Table 3.
Application of genetically modified MSCs in HCC therapy
| Transfected gene | Source of MSCs | Vector | Anti-cancer effects | ref |
|---|---|---|---|---|
| HSV-TK | Human BMSCs |
Plasmid | Reduced tumor growth in mice model and CCL5/HSV-TK-MSCs was more applicable in HCC therapy | (120) |
| PEDF | Human BMSCs |
Lentivirus | Inhibited tumor growth, microvessel density, and metastasis | (117) |
| sFIT-1 | Mice BMSCs | Adenovirus | Combination of MSC- sFlt1 and low dose doxorubicin inhibited HCC in vitro and in vivo | (116) |
| HIF-NIS | Human BMSCs |
Plasmid | systematic injection of a therapeutic dose of 131I + MSCs –NIS leads to inhibition of tumor growth and increased survival in vivo | (118) |
| IL12 | Mice BMSCs | Adenovirus | Inhibited tumor formation in mice model | (101) |
| IFN-b | Human BMSCs |
Plasmid | Lower growth rate in vitro. Inhibited HCC growth and increased the survival time in vivo. | (104) |
| siGRP78 | Human BMSCs |
Plasmid | Inhibited HCC combined with sorafenib in vitro and in vivo | (113) |
| HNF4α | Human UCMSCs | Lentivirus | Inhibited hepatoma cell proliferation and metastasis in vitro. Also inhibited tumor growth in vivo. | (119) |
| miR-122 | Human ATMSCs |
Plasmid | Enhanced chemosensitivity | (115) |
| TRAIL | Rat BMSCs |
Lentivirus | Increased apoptosis in heat-shock-treated liver cancer cells in vitro and decreased tumor growth and increased survival time in vivo. | (121) |
| TGFβ-1 | Human BMSCs |
Lentivirus | Promoted hepatoma cell proliferation and inhibited hepatoma cell migration in vitro and in vivo. | (110) |
| IFN-γ and IL-10 | Rat BMSCs |
Lentivirus | inhibited HCC in vitro and in vivo by modulating cell cycle regulators and MAPK pathway | (103) |
| IFN-b | Human BMSCs | Retrovirus | Inhibited the proliferation of HCC cells in vitro and decreased tumor growth in vivo. | (104) |
| IFN-α2b | Human BMSCs |
Plasmid | Inhibited HCC cell growth through negatively regulating the Notch signaling pathway |
(107) |
| miR-199a | Human ATMSCs |
Lentivirus | Enhanced chemosensitivity. | (114) |
| sFlt-1 | Human BMSCs |
Lentivirus | Reduced microvessel density in mice also inhibited tumor growth and prolonged survival in an HCC mouse model via systemic injection. | (151) |
| Apoptin | Human BMSCs |
Adenovirus | Inhibited proliferation of liver cancer cells (HepG2). | (125) |
| IL24 | Human UCMSCs | Adenovirus | Inhibited HepG2 cell growth, and this inhibitory effect was enhanced by low doses of 5-Fu. | (102) |
| TRAIL | Human Pancreas |
Plasmid | Inhibited cell proliferation | (122) |
| TRAIL | Human BMSCs |
Lentivirus | Inhibited HCC in combination with chemotherapeutic agents (cisplatin) in vivo. | (152) |
BMSCs: Bone marrow-derived MSCs; UCMSCs: Umbilical cord-derived MSCs; ATMSCs: Adipose tissue-derived MSCs; MSCs: Mesenchymal stem cells; CRC: Colorectal cancer